Promising cocktail for tough cancer? early trial combines immunotherapy, targeted pill, and radiation

NCT ID NCT07455019

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a combination of the immunotherapy drug bemosubaiabimab, the targeted pill anlotinib, plus radiation and chemotherapy can help people with oligometastatic esophageal cancer—cancer that has spread to a few spots. About 28 participants will receive up to 6 cycles of the combo, then continue on the two drugs alone. The main goal is to see how many patients' tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bemosubaiabimab (a drug given by IV) plus anlotinib hydrochloride (a pill taken by mouth), along with radiation and chemotherapy
What this could lead to
If it works, this could point toward a new combination treatment that shrinks tumors and delays progression in people with limited-spread esophageal cancer.
What could go wrong
This is a small, early-phase trial with only 28 people and no comparison group, so results may not apply broadly. The combination also carries risks from chemotherapy, radiation, and immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jiangsu Provincial People's Hospital

    RECRUITING

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.